Metastatic HR+/HER2- Breast Cancer Global Market Report 2025

The metastatic HR+/HER2-breast cancer market size has grown rapidly in recent years. It will grow from $9.91 billion in 2024 to $10.92 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth during the historic period can be attributed to increased awareness about early diagnosis, higher diagnosis rates, successes in clinical trials, pharmaceutical investments, and the growing adoption of combination therapies.

The metastatic HR+/HER2-breast cancer market size is expected to see strong growth in the next few years. It will grow to $15.94 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to the increasing adoption of novel therapies, a growing use of immunotherapy, expansion into emerging markets, patient advocacy and support programs, and a focus on improving quality of life. Key trends expected during this period include advancements in next-generation sequencing (NGS), liquid biopsy technologies, biomarker discovery, cell and gene therapies, and the development of monoclonal antibodies (mAbs).

The growing demand for hormone replacement therapy (HRT) is anticipated to drive the expansion of the metastatic HR+/HER2- breast cancer market in the coming years. HRT is a medical treatment used to replace or supplement hormones that are at lower levels in the body, commonly during menopause or when hormone deficiencies occur. The rising use of HRT is attributed to its effectiveness in improving treatment outcomes, fewer side effects compared to traditional therapies, and advances in precision medicine. HRT can assist metastatic HR+/HER2- breast cancer patients by relieving symptoms associated with estrogen deficiency during menopause, such as hot flashes and vaginal dryness, without affecting the efficacy of endocrine therapies. Since HRT primarily addresses hormone imbalances rather than cancerous cells, it ensures better quality of life for patients undergoing cancer treatment. For example, in October 2023, NHS England reported that 11 million HRT prescriptions were issued in England during 2022-23, a 47% increase compared to 2021-22. Consequently, the growing use of HRT is contributing to the growth of the metastatic HR+/HER2- breast cancer market.

Key companies operating in the metastatic HR+/HER2- breast cancer market are developing combination therapies to expand treatment options, market reach, and indications. Combination therapy involves using two or more therapeutic agents simultaneously, such as chemotherapy, targeted therapy, immunotherapy, hormone therapy, or other approaches. This strategy is designed to treat medical conditions more effectively by targeting different pathways, enhancing overall treatment response, and reducing the chance of resistance to a single treatment, such as cancer. For example, in July 2023, Merck & Co., Inc., a US-based pharmaceutical company, announced the Phase 3 KEYNOTE-756 trial, which evaluated KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, combined with FDA-approved chemotherapy. The trial met its primary endpoint by significantly improving the pathological complete response (pCR) rate in patients with high-risk, early-stage ER+/HER2- breast cancer. KEYNOTE-756 is the first Phase 3 trial to show a statistically significant improvement in pCR rates using an immunotherapy regimen in the neoadjuvant setting for this patient population. The trial tested KEYTRUDA with chemotherapy as neoadjuvant treatment, followed by adjuvant KEYTRUDA plus endocrine therapy for high-risk, early-stage ER+/HER2- breast cancer.

In November 2023, Carrum Health, a US-based healthcare solutions provider, entered into a partnership with Texas Oncology to enhance affordable breast cancer care. Through this collaboration, Carrum Health plans to offer a bundled package for breast cancer treatment, including two years of coverage for chemotherapy, radiation, and symptom management from Texas Oncology. This partnership aims to provide high-quality, cost-effective care. Texas Oncology, a US-based provider, specializes in treating metastatic HR+/HER2- breast cancer.

Major players in the metastatic hr+/her2- breast cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hengrui Medicine Co Ltd., MacroGenics Inc., Arvinas Inc., Olema Pharmaceuticals Inc., CytomX Therapeutics Inc., G1 Therapeutics Inc., Context Therapeutics Inc., Celcuity Inc., Sermonix Pharmaceuticals Inc., Ambrx Biopharma Inc., Carrick Therapeutics.

North America was the largest region in the dominated market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metastatic HR+/HER2- breast cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metastatic HR+/HER2- breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Metastatic HR+/HER2- breast cancer is a form of breast cancer where the cancer cells have spread from the breast to other parts of the body. Treatment typically involves targeted therapies, hormonal treatments, and chemotherapy to manage disease progression and enhance patient outcomes.

The primary drugs used for metastatic HR+/HER2- breast cancer include paclitaxel, tamoxifen, vinblastine, raloxifene, docetaxel, and other medications. Paclitaxel is a chemotherapy drug that works by stabilizing microtubules, preventing cancer cells from dividing and growing. These treatments are often combined with other approaches such as radiation therapy, vitamin therapy, macrobiotic diets, homeopathy, and herbal medicine. They are used in various healthcare settings, including hospitals, clinics, and other medical facilities.

The metastatic HR+/HER2- breast cancer market research report is one of a series of new reports that provides metastatic HR+/HER2- breast cancer market statistics, including metastatic HR+/HER2- breast cancer industry global market size, regional shares, competitors with a metastatic HR+/HER2- breast cancer market share, detailed metastatic HR+/HER2- breast cancer market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic HR+/HER2- breast cancer industry. This metastatic HR+/HER2- breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metastatic HR+/HER2- breast cancer market consists revenues earned by entities by providing services such as endocrine therapy, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic HR+/HER2- breast cancer market also includes sales of CDK4/6 inhibitors, PI3K inhibitors, mTOR inhibitors, and chemotherapy agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.